Anaemia of chronic kidney disease: what we know now.

Anoushka Krishnan, Deborah Trinder, Anita Chai-Geik Chua, Aron Chakera, Grant Ramm, John Olynyk

Research output: Contribution to journalReview article

313 Downloads (Pure)

Abstract

Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably in
the last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of a
chronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factors
and signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agents
that could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators of
hepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapies
that could be available in the near future targeting the various factors that regulate hepcidin.
Original languageEnglish
Pages (from-to)11-19
Number of pages9
JournalJournal of Renal and Hepatic Disorders
Volume1
Issue number1
DOIs
Publication statusPublished - 3 Feb 2017

Fingerprint

Hepcidins
Chronic Renal Insufficiency
Anemia
Iron
Kidney Diseases
Peptides
Health
Research

Cite this

Krishnan, Anoushka ; Trinder, Deborah ; Chua, Anita Chai-Geik ; Chakera, Aron ; Ramm, Grant ; Olynyk, John. / Anaemia of chronic kidney disease: what we know now. In: Journal of Renal and Hepatic Disorders. 2017 ; Vol. 1, No. 1. pp. 11-19.
@article{26a45bfa63394ef1a7a6ee48509ce241,
title = "Anaemia of chronic kidney disease: what we know now.",
abstract = "Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably inthe last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of achronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factorsand signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agentsthat could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators ofhepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapiesthat could be available in the near future targeting the various factors that regulate hepcidin.",
keywords = "anaemia, chronic kidney disease, iron metabolism, hepcidin, inflammation, erythropoietin-stimualting agents",
author = "Anoushka Krishnan and Deborah Trinder and Chua, {Anita Chai-Geik} and Aron Chakera and Grant Ramm and John Olynyk",
year = "2017",
month = "2",
day = "3",
doi = "10.15586/jrenhep.2017.5",
language = "English",
volume = "1",
pages = "11--19",
journal = "Journal of Renal and Hepatic Disorders",
issn = "2207-3744",
publisher = "Codon Publications",
number = "1",

}

Anaemia of chronic kidney disease: what we know now. / Krishnan, Anoushka; Trinder, Deborah; Chua, Anita Chai-Geik; Chakera, Aron; Ramm, Grant; Olynyk, John.

In: Journal of Renal and Hepatic Disorders, Vol. 1, No. 1, 03.02.2017, p. 11-19.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Anaemia of chronic kidney disease: what we know now.

AU - Krishnan, Anoushka

AU - Trinder, Deborah

AU - Chua, Anita Chai-Geik

AU - Chakera, Aron

AU - Ramm, Grant

AU - Olynyk, John

PY - 2017/2/3

Y1 - 2017/2/3

N2 - Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably inthe last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of achronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factorsand signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agentsthat could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators ofhepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapiesthat could be available in the near future targeting the various factors that regulate hepcidin.

AB - Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably inthe last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of achronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factorsand signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agentsthat could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators ofhepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapiesthat could be available in the near future targeting the various factors that regulate hepcidin.

KW - anaemia, chronic kidney disease, iron metabolism, hepcidin, inflammation, erythropoietin-stimualting agents

U2 - 10.15586/jrenhep.2017.5

DO - 10.15586/jrenhep.2017.5

M3 - Review article

VL - 1

SP - 11

EP - 19

JO - Journal of Renal and Hepatic Disorders

JF - Journal of Renal and Hepatic Disorders

SN - 2207-3744

IS - 1

ER -